Ohnuma T, Nogeire C, Cuttner J, Holland J F
Cancer. 1978 Oct;42(4):1670-9. doi: 10.1002/1097-0142(197810)42:4<1670::aid-cncr2820420403>3.0.co;2-e.
Neocarzinostatin (NCZ), an acidic polypeptide antibiotic, was given to 47 patients with cancer and leukemia, and tolerance to two schedules, a single dose given as a 2 hour infusion and a continuous infusion over 5 days was investigated. Immediate reactions, including fever, chills, rigor, hypertension and mental confusion, were dose-limiting for the 2 hour infusion schedule, occurring at 3000 U/m2 and higher. Continuous administration for 5 days eliminated the immediate reactions and then hematological toxicity--often prolonged leukopenia and thrombocytopenia--became dose-limiting. Other toxicities of NCZ at both dose schedules included anemia, fever and chills, anorexia, nausea and vomiting, hepatic dysfunction, azotemia, hypophosphatemia, aminoaciduria, stomatitis, phlebitis and/or cellulitis at the venous infusion site and pruritus. Patients with solid tumors who had received little or no prior chemotherapy and had good bone marrow reserve tolerated up to 6000 U/m2/24 hours X 5 days. One patient with previously treated acute myelocytic leukemia was induced into a good partial remission lasting 10 weeks.
新制癌菌素（NCZ）是一种酸性多肽抗生素，应用于47例癌症和白血病患者，并研究了两种给药方案的耐受性，即2小时静脉滴注单剂量给药和连续5天静脉滴注给药。对于2小时静脉滴注方案，包括发热、寒战、强直、高血压和精神错乱在内的即刻反应是剂量限制性的，在3000 U/m²及以上剂量时出现。连续给药5天消除了即刻反应，随后血液学毒性——通常是长期白细胞减少和血小板减少——成为剂量限制性因素。两种给药方案下NCZ的其他毒性包括贫血、发热和寒战、厌食、恶心和呕吐、肝功能障碍、氮质血症、低磷血症、氨基酸尿、口腔炎、静脉炎和/或静脉输液部位的蜂窝织炎以及瘙痒。接受过很少或未接受过先前化疗且骨髓储备良好的实体瘤患者耐受剂量高达6000 U/m²/24小时×5天。1例先前接受过治疗的急性髓细胞白血病患者诱导进入持续10周的良好部分缓解期。
